|
||||||||||||||||||||||
|
|
Phase III Randomized Comparison of Postoperative Adjuvant Hormonal Therapy with Tamoxifen vs Tamoxifen/Fluoxymesterone in Postmenopausal Women with ER-Positive Breast Cancer
Basic Trial Information
Objectives I. Compare relapse-free and overall survival of postmenopausal women with ER-positive breast cancer randomly assigned to adjuvant therapy with tamoxifen alone vs. tamoxifen/fluoxymesterone following resection of all known disease. Entry Criteria Disease Characteristics: Histologically confirmed adenocarcinoma of the breast Tumor excised within 6 weeks of randomization Lumpectomy patients should first be considered for protocol NCCTG-923051 One of the following pathologic stage/age combinations required: Node-negative T1c (larger than 1-2 cm) T2 N0 M0--any age Node-positive T1-2 N1 M0--age 65 and over No pectoral fascia invasion No bilateral or previous breast cancer Hormone receptor status: ER-positive (at least 10 fmoles/mg cytosol protein by standard assay or positive by immunocytochemical assay) Prior/Concurrent Therapy: Biologic therapy: No prior systemic therapy for breast cancer Chemotherapy: No prior systemic therapy for breast cancer Endocrine therapy: No prior systemic therapy for breast cancer except up to 14 days of tamoxifen Radiotherapy: No prior radiotherapy for breast cancer Radiotherapy required on protocol for patients with breast conservation therapy Surgery: Excision within 6 weeks, consisting of 1 of the following: Modified radical mastectomy OR Lumpectomy with microscopically negative margins (allowed only in patients with only 1 primary tumor and with largest diameter no greater than 5 cm) Levels I and II axillary dissection required with pathologic examination of at least 6 axillary nodes Other: No current treatment with warfarin (Coumadin) Patient Characteristics: Age: Not specified Menopausal status: Postmenopausal, i.e.: LMP more than 12 months prior to diagnosis LMP 4-12 months prior to diagnosis and FSH in the postmenopausal range FSH within postmenopausal range after discontinuing postmenopausal estrogen therapy Bilateral oophorectomy at least 2 months prior to diagnosis Hysterectomy without oophorectomy provided patient is over age 60 or has postmenopausal levels of FSH Performance status: Not specified Hematopoietic: WBC at least 3,000 Platelets at least 100,000 Hepatic: Total bilirubin or SGOT not greater than 1.5 x ULN Renal: Creatinine not greater than 2 x ULN Other: No active second cancer within 5 years except: Resected nonmelanomatous skin cancer Adequately treated in situ cervical cancer Expected Enrollment 257 patients will be required on each arm. Outline Randomized study. Patients with breast conservation surgery must also receive radiotherapy on protocol NCCTG-923051 or on Regimen A. Arm I: Antiestrogen Therapy. Tamoxifen, TMX, NSC-180973. Arm II: Antiestrogen Therapy plus Androgen Therapy. TMX; plus Fluoxymesterone, FXM, NSC-12165. Regimen A: Radiotherapy. Irradiation of the ipsilateral breast and chest wall using megavoltage equipment with peak energies no greater than 6 MeV with an electron beam or interstitial boost plus (as indicated) regional lymphatic irradiation using megavoltage equipment with peak photon energies no greater than 6 MV.Published Results Goetz MP, Moyer AM, Weinshilboum RM, et al.: Role of SULT1A1 copy number in tamoxifen treated breast cancer: findings from the North Central Cancer Treatment Group (NCCTG) adjuvant trial 89-30-52. [Abstract] J Clin Oncol 26 (Suppl 15): A-22041, 2008. Goetz MP, Suman VJ, Couch FJ, et al.: Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance. Clin Cancer Res 14 (18): 5864-8, 2008.[PUBMED Abstract] Goetz MP, Knox SK, Suman VJ, et al.: The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101 (1): 113-21, 2007.[PUBMED Abstract] Goetz MP, Suman V, Couch F, et al.: An index based on HOXB13/IL17BR and CYP2D6 for determination of relapse and survival in tamoxifen-treated node negative breast cancer. [Abstract] Breast Cancer Res Treat 100 (Suppl 1): A-1044, S53, 2006. Goetz MP, Suman VJ, Ingle JN, et al.: A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res 12 (7 Pt 1): 2080-7, 2006.[PUBMED Abstract] Ingle JN, Suman VJ, Mailliard JA, et al.: Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52. Breast Cancer Res Treat 98 (2): 217-22, 2006.[PUBMED Abstract] Goetz MP, Rae JM, Suman VJ, et al.: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23 (36): 9312-8, 2005.[PUBMED Abstract] Goetz MP, Suman VJ, Ingle JN, et al.: A two-gene expression ratio of HOXB13 and IL-17BR for prediction of recurrence and survival in women receiving adjuvant tamoxifen. [Abstract] Breast Cancer Research and Treatment 94 (Suppl 1): A-312, 2005. Goetz MP, Rae JM, Suman VJ, et al.: Pharmacogenomic determinants of outcome with tamoxifen therapy: findings from the randomized North Central Cancer Treatment Group adjuvant breast cancer trial 89-30-52. [Abstract] Breast Cancer Res Treat 88 (Suppl 1): A-314, 2004. Trial Lead Organizations North Central Cancer Treatment Group
Mayo Clinic Cancer Center
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |